| 505 |
0 |
|
|a Preface -- EBV latency -- Chap. 1. EBNA1 – Lori Frappier, University of Toronto, Canada -- Chap. 2. EBNA2 and its coactivator EBNA-LP – Bettina Kempkes, Helmholtz Center Munich, Germany, and Paul D. Ling, Baylor College of Medicine, Houston, USA -- Chap. 3. The EBNA3 family: two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells– Martin J. Allday, Quentin Bazot and Robert E. White, Imperial College London, UK. Chap. 4. The latent membrane protein 1 (LMP1) – Arnd Kieser and Kai R. Sterz, Helmholtz Center Munich, Germany. Chap. 5. Latent membrane protein 2 (LMP2) – Osman Cen and Richard Longnecker, Northwestern University, Chicago, USA. Chap. 6. EBV non-coding RNAs – Rebecca L. Skalsky and Bryan R. Cullen, Duke University, Durham, USA -- E. Lytic EBV infection -- 7. Viral entry – Liudmila S. Chesnokova, Ru Jiang1 and Lindsey M. Hutt-Fletcher, Louisiana State University, Shreveport, USA -- Chap. 8. Epstein Barr virus lytic cycle reactivation – Jessica McKenzie and Ayman El-Guindy, Yale University, New Haven, USA -- Immune responses to EBV -- Chap. 9. Innate immune recognition of EBV – Anna Lünemann and David Nadal, University of Zürich, Switzerland and Martin Rowe, University of Birmingham, UK -- Chap. 10. Epstein-Barr virus specific humoral immune responses in health and disease – Jaap M. Middeldorp, VU Medical Center, Amsterdam, The Netherlands -- Chap. 11. T cell responses to EBV – Andrew D. Hislop and Graham S. Taylor, University of Birmingham, UK -- Chap. 12. Immune evasion by Epstein Barr virus – Maaike E. Ressing, Michiel van Gent, Anna M. Gram, Marjolein Hooykaas, Sytse Piersma and Emmanuel Wiertz, Utrecht Medical Center, The Netherlands -- Animal models of EBV infection -- Chap. 13. Non-human primate lymphocryptoviruses: past, present, and future– Janine Mühe and Fred Wang, Harvard University, Boston, USA. Chap.14. EBV infection of mice with reconstituted human immune system components – Christian Münz, University of Zürich, Switzerland -- Therapy of EBV associated diseases -- Chap. 15. Adoptive T cell immunotherapy – Stephen Gottschalk and Cliona Rooney, Baylor College of Medicine, Houston, USA -- Chap. 16. The Development of Prophylactic and Therapeutic EBV Vaccines – Corey Smith and Rajiv Khanna, Queensland Institute of Medical Research, Brisbane, Australia -- Chap. 17. The biology and clinical utility of EBV monitoring in blood– Jennifer Kanakry and Richard Ambinder, Johns Hopkins University, Baltimore, USA -- Index.
|